Viatris Debt to Equity Ratio 2010-2024 | VTRS

Current and historical debt to equity ratio values for Viatris (VTRS) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Viatris debt/equity for the three months ending March 31, 2024 was 0.80.
Viatris Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-03-31 $27.33B $20.01B 1.37
2023-12-31 $27.22B $20.47B 1.33
2023-09-30 $27.88B $20.87B 1.34
2023-06-30 $27.85B $20.84B 1.34
2023-03-31 $28.36B $20.93B 1.36
2022-12-31 $28.95B $21.07B 1.37
2022-09-30 $29.48B $19.18B 1.54
2022-06-30 $31.32B $19.81B 1.58
2022-03-31 $33.02B $20.45B 1.62
2021-12-31 $34.35B $20.49B 1.68
2021-09-30 $34.93B $21.14B 1.65
2021-06-30 $36.78B $21.21B 1.73
2021-03-31 $37.57B $21.42B 1.75
2020-12-31 $38.60B $22.95B 1.68
2020-09-30 $18.70B $12.55B 1.49
2020-06-30 $18.41B $11.75B 1.57
2020-03-31 $18.88B $11.26B 1.68
2019-12-31 $19.37B $11.88B 1.63
2019-09-30 $19.59B $11.46B 1.71
2019-06-30 $19.91B $11.90B 1.67
2019-03-31 $20.02B $11.89B 1.68
2018-12-31 $20.57B $12.17B 1.69
2018-09-30 $21.39B $12.07B 1.77
2018-06-30 $21.06B $12.21B 1.73
2018-03-31 $22.01B $13.18B 1.67
2017-12-31 $22.50B $13.31B 1.69
2017-09-30 $22.53B $13.29B 1.70
2017-06-30 $22.67B $12.83B 1.77
2017-03-31 $22.62B $11.66B 1.94
2016-12-31 $23.61B $11.12B 2.12
2016-09-30 $24.71B $11.83B 2.09
2016-06-30 $18.51B $10.33B 1.79
2016-03-31 $12.37B $10.28B 1.20
2015-12-31 $12.50B $9.77B 1.28
2015-09-30 $11.50B $9.82B 1.17
2015-06-30 $13.23B $9.57B 1.38
2015-03-31 $13.03B $9.09B 1.43
2014-12-31 $12.55B $3.28B 3.83
2014-09-30 $11.77B $3.41B 3.46
2014-06-30 $12.25B $3.35B 3.65
2014-03-31 $12.16B $3.19B 3.81
2013-12-31 $12.34B $2.96B 4.17
2013-09-30 $9.67B $3.23B 2.99
2013-06-30 $9.27B $2.95B 3.15
2013-03-31 $9.00B $2.89B 3.12
2012-12-31 $8.58B $3.36B 2.56
2012-09-30 $8.08B $3.62B 2.23
2012-06-30 $8.40B $3.20B 2.63
2012-03-31 $8.16B $3.78B 2.16
2011-12-31 $8.09B $3.51B 2.31
2011-09-30 $7.62B $3.49B 2.18
2011-06-30 $8.13B $3.88B 2.09
2011-03-31 $7.96B $3.92B 2.03
2010-12-31 $7.92B $3.62B 2.19
2010-09-30 $7.86B $3.54B 2.22
2010-06-30 $7.62B $2.98B 2.56
2010-03-31 $7.64B $3.18B 2.41
2009-12-31 $7.66B $3.15B 2.43
2009-09-30 $7.69B $3.07B 2.50
2009-06-30 $7.33B $2.91B 2.52
2009-03-31 $7.25B $2.65B 2.74
Sector Industry Market Cap Revenue
Medical Medical Services $14.098B $15.427B
Viatris, Inc. is a global healthcare company. Its portfolio comprises more than thousand approved molecules across a wide range of key therapeutic areas, including globally recognized iconic and key brands, generic, complex generic, and biosimilar products. Branded products include EpiPen, Amitiza, Lipitor and Viagra. Biosimilars portfolio include pegfilgrastim, trastuzumab and adalimumab biosimilars. It has obtained approval for the biosimilar of Avastin and Insulin Aspart in Europe. The company reports in following segments: Developed Markets, Greater China, JANZ & Emerging Markets. The Developed Markets segment comprises operations in N. America and Europe. The Greater China segment operates in China, Taiwan and Hong Kong. The JANZ segment will report for operations in Japan, Australia and New Zealand, while the Emerging Markets segment will include operations in Asia, the Middle East, South and Central America, Africa and E. Europe. This segment also includes the company's anti-retroviral franchise.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $115.971B 14.14
Cencora (COR) United States $44.597B 17.39
ICON (ICLR) Ireland $27.199B 25.68
DiDi Global (DIDIY) China $17.303B 0.00
Avantor (AVTR) United States $14.163B 20.85
CochLear (CHEOY) Australia $14.103B 0.00
Revvity (RVTY) United States $13.345B 23.41
Medpace Holdings (MEDP) United States $13.053B 42.95
Natera (NTRA) United States $13.015B 0.00
Charles River Laboratories (CRL) United States $11.242B 21.52
Solventum (SOLV) United States $9.430B 0.00
Sonic Healthcare (SKHHY) Australia $8.373B 0.00
HealthEquity (HQY) United States $6.385B 40.99
Bausch + Lomb (BLCO) Canada $5.974B 23.92
Organon (OGN) United States $5.395B 5.12
Doximity (DOCS) United States $5.233B 36.65
PACS (PACS) United States $4.921B 0.00
Life Times (LTH) United States $4.146B 43.44
Sotera Health (SHC) United States $3.705B 18.18
Surgery Partners (SGRY) United States $3.692B 33.78
GoodRx Holdings (GDRX) United States $3.189B 121.43
Agilon Health (AGL) United States $2.834B 0.00
Progyny (PGNY) United States $2.646B 45.56
AMN Healthcare Services Inc (AMN) United States $2.167B 8.59
Premier (PINC) United States $2.051B 8.78
BrightSpring Health Services (BTSG) United States $2.004B 0.00
Alignment Healthcare (ALHC) United States $1.925B 0.00
Teladoc Health (TDOC) United States $1.542B 0.00
Ryman Healthcare (RYHTY) New Zealand $1.467B 0.00
Establishment Labs Holdings (ESTA) $1.251B 0.00
CareDx (CDNA) United States $0.942B 0.00
GeneDx Holdings (WGS) United States $0.831B 0.00
InnovAge Holding (INNV) United States $0.825B 0.00
Embecta (EMBC) United States $0.760B 5.16
Auna S.A (AUNA) Luxembourg $0.657B 0.00
Pediatrix Medical (MD) United States $0.633B 6.71
COMPASS Pathways (CMPS) United Kingdom $0.499B 0.00
Sharecare (SHCR) United States $0.497B 0.00
Enhabit (EHAB) United States $0.476B 47.45
Sonida Senior Living (SNDA) United States $0.407B 0.00
QDM (QDMI) Hong Kong, SAR China $0.353B 9.24
ModivCare (MODV) United States $0.335B 6.27
DocGo (DCGO) United States $0.314B 17.17
LifeMD (LFMD) United States $0.274B 0.00
MultiPlan (MPLN) United States $0.258B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
Beauty Health (SKIN) United States $0.221B 0.00
Biodesix (BDSX) United States $0.203B 0.00
Ascend Wellness Holdings (AAWH) United States $0.194B 0.00
So-Young (SY) China $0.100B 48.51
Pono Capital Two (PTWO) United States $0.068B 0.00
NeueHealth (NEUE) United States $0.043B 5.82
Co-Diagnostics (CODX) United States $0.041B 0.00
Oncology Institute (TOI) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.034B 0.00
Nutex Health (NUTX) United States $0.034B 0.00
OncoCyte (OCX) United States $0.027B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.024B 0.00
SeaStar Medical Holding (ICU) United States $0.024B 0.00
TRxADE HEALTH (MEDS) United States $0.021B 0.00
Singular Genomics Systems (OMIC) United States $0.020B 0.00
KindlyMD (KDLY) $0.017B 0.00
BIMI Holdings (BIMI) United States $0.016B 0.00
BioNexus Gene Lab (BGLC) $0.009B 0.00
XWELL (XWEL) United States $0.007B 0.00
Intelligent Bio Solutions (INBS) United States $0.005B 0.00
OpGen (OPGN) United States $0.004B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Singapore $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Assure Holdings (IONM) United States $0.002B 0.00